Trials / Completed
CompletedNCT03392116
Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects
A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM120 in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- NGM Biopharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NGM120 | Subcutaneous Injection |
| OTHER | Placebo | Subcutaneous Injection |
Timeline
- Start date
- 2018-01-29
- Primary completion
- 2019-01-14
- Completion
- 2019-03-11
- First posted
- 2018-01-05
- Last updated
- 2019-08-20
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT03392116. Inclusion in this directory is not an endorsement.